Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug. To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition. We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-molecule drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo. Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition. Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032. Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibition in BRAFV600 mutant cancers leads to loss of negative feedback signals regulated by the MAPK pathway, leading to receptor tyrosine kinase (RTK)-mediated reactivation of MAPK signaling through wild type RAS and RAF, particularly in specific tumor types, such as colorectal cancer (9–12).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This finding is consistent with prior studies identifying HER family and FGFR signaling as key mediators of adaptive feedback to RAS-MAPK pathway inhibitors (10–14,21,22) and recent functional genomic screens(40).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [159]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Figure 1e shows that inhibition of EGFR does not significantly affect proliferation of EGFR in WiDr cells, consistent with the clinical observations that KRAS or BRAF mutant CRC cells do not respond to EGFR-targeted monoclonal antibodie”
ResultEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Cited by
Items 501–600 of 1,012
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 71
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Ye, J., Wu, J., & Liu, B. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188866 · Cited by 70
Park, S., & Lehner, B. (2015) · Molecular Systems Biology · doi:10.15252/msb.20156102 · Cited by 61
Middleton, G., Yang, Y., Campbell, C. D., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3579 · Cited by 63
METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation
Bhattarai, P. Y., Kim, G., Poudel, M., Lim, S., & Choi, H. S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.015 · Cited by 65
Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
Joshi, M., Rice, S. J., Liu, X., Miller, B., & Belani, C. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118210 · Cited by 64
Kayhanian, H., Goode, E., Sclafani, F., Ang, J. E., Gerlinger, M., de Castro, D. G., Shepherd, S. T. C., Peckitt, C., Rao, S., Watkins, D. J., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.006 · Cited by 67
Mizukami, T., Izawa, N., Nakajima, T. E., & Sunakawa, Y. (2019) · Drugs · doi:10.1007/s40265-019-01113-0 · Cited by 65
Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer
Baraibar, I., Mirallas, O., Gonzalez, N. S., Ros, J., Salvà, F., Tabernero, J. M., & Élez, E. (2021) · Cancers · doi:10.3390/cancers13246311 · Cited by 67
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 66
Markers of resistance to anti-EGFR therapy in colorectal cancer.
Shaib, W. L., Mahajan, R., & El‐Rayes, B. F. (2013) · PubMed · doi:10.3978/j.issn.2078-6891.2013.029 · Cited by 53
Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals
Wang, Y., Ou, Z., Sun, Y., Yeh, S., Wang, X., Long, J., & Chang, C. (2016) · Oncogene · doi:10.1038/onc.2016.330 · Cited by 71
Not all cancers are created equal: Tissue specificity in cancer genes and pathways
Bianchi, J. J., Zhao, X., Mays, J. C., & Davoli, T. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.01.005 · Cited by 77
BRAF mutation in colorectal cancer: An update
Colombo, A., Porretto, C. M., & Rosati, G. (2022) · Archive of oncology · doi:10.2298/aoo220130004c · Cited by 61
Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0016-1 · Cited by 60
Self-citationWorkman, P., Al‐Lazikani, B., & Clarke, P. A. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.06.004 · Cited by 65
Improving the anti-colon cancer activity of curcumin with biodegradable nano-micelles
Gao, X., Zheng, F., Guo, G., Liu, X., Fan, R., Qian, Z.-Y., Huang, N., & Wei, Y.-Q. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb21091j · Cited by 59
TRIM28 Is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming
Miles, D. C., de Vries, N. A., Gisler, S., Lieftink, C., Akhtar, W., Gogola, E., Pawlitzky, I., Hulsman, D., Tanger, E., Koppens, M. A. J., et al. (2016) · Stem Cells · doi:10.1002/stem.2453 · Cited by 64
Self-citationThe therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer
Bahrami, A., Hesari, A., Khazaei, M., Hassanian, S. M., Ferns, G. A., & Avan, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25952 · Cited by 64
Toon, C. W., Chou, A., DeSilva, K., Chan, J., Patterson, J., Clarkson, A., Sioson, L., Jankova, L., & Gill, A. J. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.200 · Cited by 59
BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma
Affolter, K. E., Samowitz, W. S., Tripp, S. R., & Bronner, M. P. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22070 · Cited by 59
Dienstmann, R., Elez, E., Argiles, G., Matos, I., Sanz‐Garcia, E., Ortiz, C., Macarulla, T., Capdevila, J., Alsina, M., Sauri, T., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12099 · Cited by 56
Martini, G., Ciardiello, D., Vitiello, P. P., Napolitano, S., Cardone, C., Cuomo, A., Troiani, T., Ciardiello, F., & Martinelli, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102023 · Cited by 58
Sammarco, G., Gallo, G., Vescio, G., Picciariello, A., Paola, G. D., Trompetto, M., Currò, G., & Ammendola, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092852 · Cited by 61
Day, F. L., Murányi, A., Singh, S., Shanmugam, K., Williams, D., Byrne, D. J., Pham, K., Palmieri, M., Tie, J., Grogan, T. M., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0319-8 · Cited by 63
Bid, H. K., Kibler, A., Phelps, D. A., Manap, S., Xiao, L., Lin, J., Capper, D., Oswald, D. J., Geier, B., DeWire, M. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0842 · Cited by 63
Syn, N. L. X., Yong, W. P., Goh, B. C., & Lee, S. C. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1196187 · Cited by 76
Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era
Porta‐Pardo, E., Valencia, A., & Godzik, A. (2020) · FEBS Letters · doi:10.1002/1873-3468.13781 · Cited by 68
Sale, M. J., & Cook, S. J. (2013) · Biochemical Journal · doi:10.1042/bj20121212 · Cited by 58
Additivity predicts the efficacy of most approved combination therapies for advanced cancer
Hwangbo, H., Patterson, S. C., Dai, A., Plana, D., & Palmer, A. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00667-z · Cited by 71
Adaptive resistance to RAF inhibitors in melanoma
Kugel, C. H., & Aplin, A. E. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12264 · Cited by 64
Prat, A., Adamo, B., Fan, C., Peg, V., Vidal, M. J., Galván, P., Vivancos, A. P., Nuciforo, P. G., Pálmer, H. G., Dawood, S. S., et al. (2013) · Scientific Reports · doi:10.1038/srep03544 · Cited by 65
BRAFmutations in chronic lymphocytic leukemia
Jebaraj, B. M. C., Kienle, D., Bühler, A., Winkler, D. F. H., Döhner, H., Stilgenbauer, S., & Zenz, T. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.742525 · Cited by 60
Chen, C., Li, X. N., Yuan, S., Antonijevic, Z., Kalamegham, R., & Beckman, R. A. (2016) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2016.1193044 · Cited by 58
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Marmorino, F., Boccaccino, A., Germani, M. M., Falcone, A., & Cremolini, C. (2020) · Cancers · doi:10.3390/cancers12082317 · Cited by 56
Exploring liver cancer biology through functional genetic screens
Wang, C., Cao, Y., Yang, C. G., Bernards, R., & Qin, W. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00465-x · Cited by 60
Self-citationHutchinson, R. A., Adams, R., McArt, D. G., Salto‐Tellez, M., Jasani, B., & Hamilton, P. W. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0531-z · Cited by 62
Improving outcomes in colorectal cancer: Where do we go from here?
Cutsem, E. V., Borràs, J. M., Castells, A., Ciardiello, F., Ducreux, M. P., Haq, A., Schmoll, H., & Tabernero, J. M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.026 · Cited by 64
Erlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals
Miyabayashi, K., Ijichi, H., Mohri, D., Tada, M., Yamamoto, K., Asaoka, Y., Ikenoue, T., Tateishi, K., Nakai, Y., Isayama, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1453 · Cited by 61
Tang, B., Xie, R., Qin, Y., Xiao, Y., Yong, X., Zheng, L., Dong, H. F., & Yang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6575 · Cited by 62
BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells
He, K., Chen, D., Ruan, H., Li, X., Tong, J., Xu, X. M., Zhang, L., & Yu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10277 · Cited by 61
Wang, V. E., Xue, J. Y., Frederick, D. T., Cao, Y., Lin, E., Wilson, C., Urisman, A., Carbone, D. P., Flaherty, K. T., Bernards, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2779 · Cited by 54
Self-citationMolecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Martini, G., Dienstmann, R., Ros, J., Baraibar, I., Cuadra‐Urteaga, J. L., Salvà, F., Ciardiello, D., Mulet-Margalef, N., Argilés, G., Tabernero, J. M., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936089 · Cited by 63
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
Olivier, T., Fernández, E., Labidi‐Galy, S. I., Dietrich, P., Rodríguez-Bravo, V., Baciarello, G., Fizazi, K. S., & Patrikidou, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102204 · Cited by 68
Emerging treatment options for BRAF-mutant colorectal cancer
Ursem, C., Atreya, C. E., & Van Loon, K. (2018) · Gastrointestinal Cancer: Targets and Therapy · doi:10.2147/gictt.s125940 · Cited by 47
Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
Grassi, E., Corbelli, J., Papiani, G., Barbera, M. A., Gazzaneo, F., & Tamberi, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.601722 · Cited by 59
Tan, L., Tran, B., Tie, J., Markman, B., Ananda, S., Tebbutt, N. C., Michael, M., Link, E. K., Wong, S. Q., Chandrashekar, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3094 · Cited by 59
Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies
Bagrodia, S., Smeal, T., & Abraham, R. T. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12007 · Cited by 59
Lantermann, A. B., Chen, D., McCutcheon, K., Hoffman, G., Frias, E., Ruddy, D., Rakiec, D., Korn, J., McAllister, G., Stegmeier, F., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1113 · Cited by 55
Bianchi, A. S., Loupakis, F., Argilés, G., & Prager, G. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw191 · Cited by 58
Synthetic Lethality in Cancer Therapeutics
Beijersbergen, R. L., Wessels, L. F. A., & Bernards, R. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042016-073434 · Cited by 62
Self-citationTargeted Therapy for Medullary Thyroid Cancer: A Review
Priya, S. R., Dravid, C. S., Digumarti, R., & Dandekar, M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00238 · Cited by 58
Precision medicine for metastatic colorectal cancer: an evolving era
Güler, İ., Aşkan, G., Klostergaard, J., & Şahin, İ. H. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1663174 · Cited by 60
Molecular therapeutics for anaplastic thyroid cancer
Pozdeyev, N. V., Rose, M. M., Bowles, D. W., & Schweppe, R. E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.005 · Cited by 61
BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
Nakayama, I., Hirota, T., & Shinozaki, E. (2020) · Cancers · doi:10.3390/cancers12113236 · Cited by 65
van Geel, R. M. J. M., van Brummelen, E. M. J., Eskens, F. A. L. M., Huijberts, S. C. F. A., de Vos, F. Y. F. L., Lolkema, M. P. J. K., Devriese, L. A., Opdam, F. L., Marchetti, S., Steeghs, N., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0776-z · Cited by 55
Self-citationWang, X., Jiang, W., Du, Y., Dongqi, Z., Zhang, J., Fang, C., Fang, Y., & Chen, Z.-S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100884 · Cited by 55
Lou, Y.-F., Zou, Z.-Z., Chen, P.-J., Huang, G.-B., Li, B., Zheng, D.-Q., Yu, X.-R., & Luo, X.-Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097719 · Cited by 54
Renovanz, M., & Kim, E. L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00142 · Cited by 64
What are we learning from the cancer genome?
Collisson, E. A., Cho, R. J., & Gray, J. W. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.159 · Cited by 59
DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?
Voest, E. E., & Bernards, R. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1321 · Cited by 54
Self-citationSerrated Colorectal Cancer: The Road Less Travelled?
Nakanishi, Y., Díaz-Meco, M. T., & Moscat, J. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.004 · Cited by 60
Model‐Based Nanoengineered Pharmacokinetics of Iron‐Doped Copper Oxide for Nanomedical Applications
Naatz, H., Manshian, B. B., Ríos‐Luci, C., Tsikourkitoudi, V. P., Deligiannakis, Y. G., Birkenstock, J., Pokhrel, S., Mädler, L., & Soenen, S. J. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201912312 · Cited by 61
Yang, G., Yan, Y., Ma, Y., & Yang, Y. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22654 · Cited by 54
“A previous study suggested that the lack of responsiveness of colon cancer to BRAF inhibition was due to a feedback activation of EGFR.(29) However, feedback activation of BRAF and ERK in response to BRAF inhibition by PLX4032 has not been reported.”
BackgroundMartin, S., Dudek-Perić, A. M., Maes, H., Garg, A. D., Gabrysiak, M., Demirsoy, S., Swinnen, J. V., & Agostinis, P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.003 · Cited by 54
“signalling can proceed unabated [13] and to a degree that can still support their drug resistance, even under conditions of autophagy mitigation [14].”
BackgroundGarrido-Laguna, I., Hong, D. S., Janku, F., Nguyen, L. M., Falchook, G. S., Fu, S., Wheler, J. J., Luthra, R., Naing, A., Wang, X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038033 · Cited by 52
BRAF: A Driver of the Serrated Pathway in Colon Cancer
Rustgi, A. K. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.008 · Cited by 62
Small Molecule Agonists of PPAR-γ Exert Therapeutic Effects in Esophageal Cancer
Sawayama, H., Ishimoto, T., Watanabe, M., Yoshida, N., Sugihara, H., Kurashige, J., Hirashima, K., Iwatsuki, M., Baba, Y., Oki, E., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1836 · Cited by 57
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era
Seow, H. F., Yip, W. K., & Fifis, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s95101 · Cited by 59
Targeted Therapy of Colorectal Cancer
Seeber, A., & Gastl, G. A. (2016) · Oncology Research and Treatment · doi:10.1159/000453027 · Cited by 66
Natural scaffolds in anticancer therapy and precision medicine
Mazumder, A., Cerella, C., & Diederich, M. F. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.009 · Cited by 56
Stratification and prediction of drug synergy based on target functional similarity
Yang, M., Jaaks, P., Dry, J. R., Garnett, M. J., Menden, M. P., & Sáez-Rodríguez, J. (2020) · npj Systems Biology and Applications · doi:10.1038/s41540-020-0136-x · Cited by 62
Şahin, İ. H., & Klostergaard, J. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00160 · Cited by 67
Taking advantage of drug resistance, a new approach in the war on cancer
Wang, L., & Bernards, R. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0647-7 · Cited by 53
Self-citationTargeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Ros, J., Vaghi, C., Baraibar, I., Gonzalez, N. S., Rodríguez-Castells, M., García, A., Alcaráz, A., Salvà, F., Tabernero, J. M., & Élez, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063304 · Cited by 62
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Wei, J., Lu, M., Wei, T., Fleishman, J. S., Yu, H. J., Chen, X.-L., Kong, X.-T., Sun, S., Li, N., Yang, Y., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101229 · Cited by 60
Activating BRAF V600E Mutation in Aggressive Pediatric Langerhans Cell Histiocytosis
Méhes, G., Irsai, G., Bedekovics, J., Beke, L., Fazakas, F., Rózsa, T., & Kiss, C. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000304 · Cited by 53
Troiani, T., Zappavigna, S., Martinelli, E., Addeo, S. R., Stiuso, P., Ciardiello, F., & Caraglia, M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.756469 · Cited by 53
Ascierto, P. A., Atkins, M. B., Bifulco, C. B., Botti, G., Cochran, A. J., Davies, M. A., Demaria, S., Dummer, R., Ferrone, S., Formenti, S. C., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0736-1 · Cited by 53
Zou, Z., Nie, P., Li, Y., Hou, B., Rui-li, Shi, X., Ma, Z., Han, B., & Luo, X. (2015) · Oncotarget · doi:10.18632/oncotarget.5628 · Cited by 56
Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches
Strickler, J. H., Wu, C. S.-Y., & Bekaii‐Saab, T. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.006 · Cited by 58
Remodelling of primary human CD4+T cell plasma membrane order byn-3 PUFA
Fan, Y.-Y., Fuentes, N. R., Hou, T. Y., Barhoumi, R., Li, X. C., Deutz, N. E. P., ENGELEN, M. P. K. J., McMurray, D. N., & Chapkin, R. S. (2017) · British Journal Of Nutrition · doi:10.1017/s0007114517003385 · Cited by 56
Thinking Differently about Cancer Treatment Regimens
Settleman, J., Neto, J. M. F., & Bernards, R. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1187 · Cited by 55
Self-citationDefining and Targeting BRAF Mutations in Solid Tumors
Halle, B. R., & Johnson, D. B. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00827-2 · Cited by 57
Sa, R., Liang, R., Qiu, X., He, Z., Liu, Z., & Chen, L. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.005 · Cited by 59
Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma
Azuaje, F. J., Tiemann, K., & Niclou, S. P. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0098-6 · Cited by 56
Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer
Lin, L., Fei, X., Chen, L., Yao, L., & Lei, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1381251 · Cited by 53
B-Raf Inhibitors Induce Epithelial Differentiation in BRAF -Mutant Colorectal Cancer Cells
Herr, R., Köhler, M., Andrlová, H., Weinberg, F., Möller, Y., Halbach, S., Lutz, L., Mastroianni, J., Klose, M., Bittermann, N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-13-3686 · Cited by 57
Time to re‐consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma
Gandolfi, G., Sancisi, V., Piana, S., & Ciarrocchi, A. (2014) · International Journal of Cancer · doi:10.1002/ijc.28976 · Cited by 58
Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance
Smith, M. P., & Wellbrock, C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0954 · Cited by 51
Liu, L., Jin, X., Hu, C., Zhang, Y., Zhou, Z., Li, R., & Shen, C. (2018) · Basic Research in Cardiology · doi:10.1007/s00395-018-0669-y · Cited by 52
RetractedBasket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
Chen, Y., & Chi, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0622-4 · Cited by 55
Preclinical models for precision oncology
Ibarrola‐Villava, M., Cervantes, A. M. R., & Bardelli, A. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.004 · Cited by 58
Self-citationChen, N., & Lee, J. J. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280220910186 · Cited by 59
Resistance looms for KRASG12C inhibitors
Hata, A. N., & Shaw, A. T. (2020) · Nature Medicine · doi:10.1038/s41591-020-0765-z · Cited by 51
Alexander, P. B., & Wang, X. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0396-9 · Cited by 54
Tarabichi, M., Antoniou, A., Saiselet, M., Pita, J. M. G., Andry, G., Dumont, J. E., Detours, V., & Maenhaut, C. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9431-y · Cited by 52
Bajpe, P. K., Prahallad, A., Horlings, H. M., Nagtegaal, I. D., Beijersbergen, R. L., & Bernards, R. (2014) · Oncogene · doi:10.1038/onc.2013.588 · Cited by 53
Self-citationGraziani, V., Scognamiglio, M., Belli, V., Esposito, A., D’Abrosca, B., Chambery, A., Russo, R., Panella, M., Russo, A., Ciardiello, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23704-9 · Cited by 57
Metadata
- Authors
- Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2012-01-26
- Volume
- 483
- Issue
- 7387
- Pages
- 100-103
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014881369
- Semantic Scholar
- 10564d8dc4a3ddb05a84b5a3ca8b7b622c5c17ea
- Cited by
- 2,051
- References
- 22
- Citations by year
- 2026: 75 · 2025: 81 · 2024: 106 · 2023: 145 · 2022: 126 · 2021: 168 · 2020: 145 · 2019: 117 · 2018: 139 · 2017: 129 · 2016: 149 · 2015: 215 · 2014: 188 · 2013: 172 · 2012: 91
- FWCI
- 105.49
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- European Commission (259015)
- Ministero della Salute
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KWF Kankerbestrijding
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- BRAF V600E mutation, colon cancer, EGFR, vemurafenib, drug resistance, feedback activation, cetuximab, gefitinib, erlotinib, combination therapy, RNAi screen, melanoma, targeted therapy
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Gefitinib, Vemurafenib, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Drug Synergism, Enzyme Activation, Female, Humans, Indoles, Melanoma, Quinazolines, Sulfonamides, Colorectal Neoplasms, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Feedback, Physiological, RNA Interference, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, HEK293 Cells, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.